Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors
Status:
Suspended
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
Clinical study of oral IGF-1R inhibitor PL225B in subjects with advanced refractory solid
tumors. The primary objective is to determine the maximum tolerated dose and dose limiting
toxicity (ies) of oral IGF-1R inhibitor PL225B in subjects with advanced refractory solid
tumors.